Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: A multicenter performance evaluation study

Transfusion

Volumn 55, Issue 9, 2015, Pages 2246-2255

  Grabarczyk, Piotr ^a   Koppelman, Marco ^b   Boland, Fiona ^c   Sauleda, Silvia ^d   Fabra, Cécile ^e   Cambie, Giuseppe ^f   Kopacz, Aneta ^a   O'Riordan, Karen ^c   Van Drimmelen, Harry ^g   O'Riordan, Joan ^c   Lelie, Nico ^h  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b CENTRAL LABORATORY   (Netherlands)

^c IRISH BLOOD TRANSFUSION SERVICE   (Ireland)

^d BANC DE SANG I TEIXITS   (Spain)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

^f Lodi Hospital   (Italy)

^g Biologicals Quality Control   (Netherlands)

^h Lelie Research   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; OLIGONUCLEOTIDE; VIRUS RNA;

ALGORITHM; ARTICLE; CALIBRATION; DILUTION; EVALUATION STUDY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INTERNATIONAL STANDARD UNIT; LIMIT OF DETECTION; SEROCONVERSION; VIRUS DETECTION; VIRUS REPLICATION; BLOOD; BLOOD DONOR; CLINICAL TRIAL; DONOR SELECTION; FEMALE; HEPACIVIRUS; MALE; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PROCEDURES; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

BLOOD DONORS; DONOR SELECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B VIRUS; HIV-1; HIV-2; HUMANS; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 84941803409     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13193     Document Type: Article

References (30)

1. Grabarczyk P, Van Drimmelen H, Kopacz A, et al., Head to head comparison of two transcription mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 in blood donors. Transfusion 2013; 53: 2512-24.
2. Vermeulen M, Coleman C, Mitchel J, et al., Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections. Transfusion 2013; 53: 2459-06.
3. Vermeulen M, Coleman C, Van Drimmelen H, et al, Enhanced detection of window period and occult hepatitis B infection by the Ultrio Plus assay in donor samples with varying HBV-DNA concentrations [Abstract 4A-S12-02]. Vox Sang 2013; 105 (Suppl): 56.
4. Tsoi WC, Lelie N, Lin CK,. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay. Transfusion 2013; 53: 2477-88.
5. Stramer SL, Krysztof DE, Brodsky JP, et al., Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion 2013; 53: 2525-37.
6. L318/25 Official Journal of the European Union. Commission Decision of 27 November 2009 amending decision 2002/364/EC on common technical specifications for in vitro-diagnostic medical devices (notified under document C(2009) 9464) (Text with EEA relevance) (2009/886/EC).
7. Assal A, Barlet V, Deschaseaux M, et al., Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009; 49: 289-300.
8. Van Drimmelen H, Bremer C, Gerlich W, et al., Commutability of inactivated or lyophilised virus in external quality control (EQC) samples for NAT. Rome: SoGAT XXII; 14-15 Apr 2011 [cited 2015 May 26]. Available from: http://webarchive.nationalarchives.gov.uk/20100305005801/ http://nibsc.ac.uk/spotlight/sogat/blood-virology/past-meetings.aspx
9. Laperche S, Nübling M, Stramer S, et al., Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global genotype panel of seronegative window period samples. Transfusion, in press.
10. Chudy M, Hanschmann KM, Kress J, et al., First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol. 2012; 55: 303-9.
11. Deras ML, Pekny K, Self D, et al., Performance characteristics of the Procleix Ultrio Elite assay on the fully automated Procleix Panther instrument platform [Abstract P-253]. Vox Sang 2012; 103 (Suppl 1): 147.
12. Lelie N, Van Drimmelen H;, International NAT Study Group. Calibration and stability of WHO and secondary viral standards [Internet]. Ljubljana (Slovenija): SoGAT XXIV; 8-9 May 2013 [cited 2015 May 26]. Available from: http://webarchive.nationalarchives.gov.uk/20100305005801/ http://nibsc.ac.uk/spotlight/sogat/blood-virology/past-meetings.aspx
13. Collins ML, Zayati C, Detmer JJ, et al., Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995; 226: 120-9.
14. Heermann KK, Gerlich WH, Chudy M, et al., Quantitative detection of hepatitis B virus DNA in two international reference preparations. J Clin Microbiol 1999; 37: 68-73.
15. Lelie N, Bruhn R, Custer B, et al,. Prevalence of HBV infection in six geographical regions and clinical sensitivity of HBsAg and HBV-DNA screening [Abstract 4A-S32-01]. Vox Sang 2013; 105 (Suppl): 65.
16. Bruhn R, Lelie N, Custer B, et al., Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion 2013; 53: 2399-412.
17. Bruhn R, Lelie N, Busch M, et al., The International NAT Study Group. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion 2015; 55: 1195-205.
18. Nübling CM, Heiden M, Chudy M, et al., Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009; 49: 1850-8.
19. Schmidt M, Korn K, Nübling CM, et al., First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009; 49: 1836-44.
20. Chudy M, Weber-Schehl M, Pichl L, et al., Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion 2012; 52: 431-9.
21. Müller B, Nübling CM, Kress J, et al., How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing. Transfusion 2013; 53: 2422-30.
22. Foglieni B, Candotti D, Guarnori I, et al., A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011; 51: 719-30.
23. Vermeulen M, Coleman C, Mitchel J, et al., Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Transfusion 2013; 53: 2384-98.
24. El Ekiaby M, Allain JP, Linnen J, et al., Hepatitis B virus DNA and hepatitis B surface antigen concentrations in Egyptian blood donors; limits of detection of ultrasensitive nucleic acid screening tests in HBsAg carriers [Abstract 2A-S04-02]. Vox Sang 2009; 96 (Suppl 1): 17-8.
25. Vermeulen M, Dickens C, Lelie N, et al., Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2011; 52: 880-92.
26. Vermeulen M, Coleman C, Walker V, et al., Transmission of occult HBV infection by ID-NAT screened blood [Abstract P273]. Vox Sang 2014; 107 (Suppl 1): 146-7.
27. Levicnik Stezinar S, Pajk J, Assennato M, et al., Fresh-frozen plasma from anti-HBc positive donor with undetectable HBV DNA transmitted hepatitis B virus to two recipients [Abstract P275]. Vox Sang 2014; 107 (Suppl 1): 147-8.
28. Schüttler CG, Caspari G, Jursch CA, et al., Hepatitis C transmission by a blood donation negative in nucleic acid amplification tests for viral RNA [letter to editor]. Lancet 2000; 355: 41-2.
29. Kretzschmar E, Chudy M, Nübling CM, et al., First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007; 92: 297-301.
30. Van Drimmelen AA, Assal A, Lelie PN, et al., Correlation between HBsAg and HBV-DNA concentration in seroconversion ramp up phase allows for modeling window periods from analytical sensitivity studies of HBV assays [Abstract 5D-S45-05]. Vox Sang 2010; 99 (Suppl 1): 78-9.